Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions

摘要: Whereas first-line chemotherapy (CT) with single-agent gemcitabine or gemcitabine-based combinations provides a proven benefit in patients locally advanced metastatic pancreatic cancer (PC), the role of salvage CT after gemcitabine-failure is not well-established and to date no regimen has emerged as preferred this setting. Several clinical trials have investigated efficacy toxicity-profile second-line indicated that selected may obtain significant from it, also regard survival. However, definitive results large randomized phase III studies are still lacking, evidence for based on small II evaluated different treatment schedules heterogeneous populations. The main goal paper reviewing topic.